ArticleNeurosurgery practice2025
Antitumor Effect of Selumetinib for Brainstem Glioma in an Adult With NF1: A Case Report.
Article in Neurosurgery practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and importanceNF1 is a known tumor predisposition syndrome associated with various tumors of the nervous system, including low-grade glioma in the pediatric population. NF1-associated brainstem tumors are less clinically progressive and rarely result in early death. However, a small subset of brainstem gliomas may act more aggressively in adults, especially when contrast enhancement appears. However, standard therapy for NF1-associated brainstem glioma remains controversial, and there is limited information available on the pathological and genetic findings. CLINICAL PRESENTATION: A 38-year-old man presented with diplopia and was diagnosed with a midbrain tumor on MRI. The tumor increased in size during a 2-month follow-up period, and the patient underwent an open biopsy by the occipital transtentorial approach. Histopathological diagnosis revealed a low-grade glioma, isocitrate dehydrogenase wild type, and H3 wild type. An DISCUSSION AND
conclusionPrimary treatment with MAPK kinase inhibitors can lead to tumor regression in brainstem glioma in an adult patient with NF1. We recommend that patients with brainstem glioma undergo biopsy and mutation testing, especially those with an unusually aggressive clinical course.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.